Effects of Chronic Vardenafil Treatment Persist after End of Treatment in Rats with Acute Arteriogenic Erectile Dysfunction

被引:16
|
作者
Hotta, Yuji [1 ]
Ohno, Risa [1 ]
Kataoka, Tomoya [1 ]
Mikumo, Mayumi [1 ]
Takahata, Yu [1 ]
Ohno, Masae [1 ]
Maeda, Yasuhiro [1 ]
Kimura, Kazunori [1 ,2 ,3 ]
机构
[1] Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Hosp Pharm, Nagoya, Aichi, Japan
[2] Nagoya City Univ, Grad Sch Med Sci, Dept Clin Pharm, Nagoya, Aichi, Japan
[3] Nagoya City Univ, Sch Med, Nagoya, Aichi 467, Japan
来源
JOURNAL OF SEXUAL MEDICINE | 2012年 / 9卷 / 07期
关键词
Arteriogenic; Erectile Dysfunction; Chronic PDE5 Inhibitor Therapy; Vardenafil; Structure; Improvement of Erectile Function; ENDOTHELIAL GROWTH-FACTOR; PENILE CORPORA CAVERNOSA; ENHANCES ANGIOGENESIS; SMOOTH-MUSCLE; MODEL; PHOSPHODIESTERASE-5; INHIBITORS; FIBROSIS; CULTURES; PATHWAY;
D O I
10.1111/j.1743-6109.2012.02742.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. In our previous study, chronic vardenafil treatment improved erectile function soon after the end of the treatment in rats with acute arteriogenic erectile dysfunction (ED). Aim. The aim of this study is to evaluate whether the effects of chronic vardenafil treatment persist after the end of treatment using rats with acute arteriogenic ED. Methods. Rats were randomly divided into three groups: (i) control; (ii) ligation; and (iii) vardenafil + no treatment. Rats in the ligation and vardenafil + no treatment groups underwent ligature of the bilateral internal iliac arteries to induce acute arteriogenic ED and were subsequently treated with vehicle or vardenafil (4.0 mg/kg/day), respectively, for 3 weeks. Subsequently, all rats were kept for a further 2 weeks with no treatment. Rats in the control group underwent sham surgery. Main Outcome Measures. Erectile function was assessed by changes in intracavernous pressure (ICP). Smooth muscle (SM)/collagen ratios in corpus cavernosum were analyzed by Masson trichrome staining. Transforming growth factor-beta;1 (TGF-beta;1) mRNA and protein levels in corpus cavernosum (CC) were, respectively, evaluated by real-time polymerase chain reaction (PCR) analysis and Western blotting analysis. Results. ICP/mean arterial pressure (MAP) in the ligation group remained significantly lower than that in control group (P < 0.01). Despite no treatment for 2 weeks, ICP/MAP in the var + no treatment group remained significantly higher than that in ligation group (P < 0.05). SM/collagen ratio in the ligation group remained significantly lower when compared with the control group (P < 0.01). The ratio in the var + no treatment group remained significantly higher when compared with the ligation group at 2 weeks after the end of treatment (P < 0.05). TGF-beta 1 mRNA and protein levels did not differ among the groups. Conclusions. The effects of chronic vardenafil treatment on erectile function and penile structure persist, even after the end of treatment, in acute arteriogenic ED rats. Hotta Y, Ohno R, Kataoka T, Mikumo M, Takahata Y, Ohno M, Maeda Y, and Kimura K. Effects of chronic vardenafil treatment persist after end of treatment in rats with acute arteriogenic erectile dysfunction. J Sex Med 2012;9:17991805.
引用
收藏
页码:1782 / 1788
页数:7
相关论文
共 50 条
  • [1] THE EFFECT OF DAILY TREATMENT OF VARDENAFIL REMAINED AFTER THE END OF THE TREATMENT IN RATS WITH ARTERIOGENIC ERECTILE DYSFUNCTION
    Hotta, Y.
    Ohno, R.
    Kataoka, T.
    Shiota, A.
    Ohno, M.
    Kimura, K.
    JOURNAL OF SEXUAL MEDICINE, 2010, 7 : 204 - 204
  • [2] Chronic Vardenafil Treatment Improves Erectile Function via Structural Maintenance of Penile Corpora Cavernosa in Rats with Acute Arteriogenic Erectile Dysfunction
    Hotta, Yuji
    Hattori, Mayuko
    Kataoka, Tomoya
    Ohno, Risa
    Mikumo, Mayumi
    Maeda, Yasuhiro
    Kimura, Kazunori
    JOURNAL OF SEXUAL MEDICINE, 2011, 8 (03): : 705 - 711
  • [3] Development of collateral circulation and structural maintenance of corpora cavernosum by chronic vardenafil treatment in rats with arteriogenic erectile dysfunction
    Hotta, Y.
    Hattori, M.
    Kawano, M.
    Kataoka, T.
    Hori, E.
    Mikumo, M.
    Ono, R.
    Maeda, Y.
    Kimura, K.
    JOURNAL OF SEXUAL MEDICINE, 2009, 6 : 403 - 403
  • [4] Vardenafil treatment for erectile dysfunction
    Crowe, SM
    Streetman, DS
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (01) : 77 - 85
  • [5] Effective treatment of erectile dysfunction with vardenafil
    Martín-Morales, A
    Rosen, RC
    DRUGS OF TODAY, 2003, 39 (01): : 51 - 59
  • [6] Vardenafil: A new oral treatment for erectile dysfunction
    Eardley, I
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (08) : 801 - 806
  • [7] Vardenafil: A new approach to the treatment of erectile dysfunction
    Wayne J. G. Hellstrom
    Current Urology Reports, 2003, 4 (6) : 479 - 487
  • [8] Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence
    Martin Morales, Antonio
    Mirone, Vincenzo
    Dean, John
    Costa, Pierre
    CLINICAL INTERVENTIONS IN AGING, 2009, 4 : 463 - 472
  • [9] Vardenafil -: Treatment of erectile dysfunction -: Phosphodiesterase 5 inhibitor
    Sorbera, LA
    Martin, L
    Rabasseda, X
    Castañer, J
    DRUGS OF THE FUTURE, 2001, 26 (02) : 141 - 144
  • [10] A new orodispersible vardenafil formulation for the treatment of erectile dysfunction
    Gutierrez Hernandez, Pedro Ramon
    REVISTA INTERNACIONAL DE ANDROLOGIA, 2011, 9 (01): : 21 - 29